Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery
| Status: | Recruiting | 
|---|---|
| Conditions: | Ocular, Ocular | 
| Therapuetic Areas: | Ophthalmology | 
| Healthy: | No | 
| Age Range: | 40 - 80 | 
| Updated: | 12/26/2018 | 
| Start Date: | August 28, 2018 | 
| End Date: | September 1, 2019 | 
| Contact: | David Goffredo | 
| Email: | dgoffredo@rxsight.com | 
| Phone: | 949-421-5463 | 
A Prospective, Randomized, Controlled, Multi-center Clinical Study to Evaluate the Safety and Effectiveness of the RxSight Light Adjustable Lens (LAL) in Subjects With Prior Corneal Refractive Surgery
The primary objective of this study is to evaluate, for the visual correction of aphakia, the
safety and effectiveness of the RxSight Light Adjustable Lens (LAL) and Light Delivery Device
(LDD) to reduce postoperative refractive error and improve uncorrected distance visual acuity
in eyes with prior corneal refractive surgery. A control group consisting of fellow eyes
implanted with a commercially available monofocal IOL will be used to compare the safety and
effectiveness of the LAL.
			safety and effectiveness of the RxSight Light Adjustable Lens (LAL) and Light Delivery Device
(LDD) to reduce postoperative refractive error and improve uncorrected distance visual acuity
in eyes with prior corneal refractive surgery. A control group consisting of fellow eyes
implanted with a commercially available monofocal IOL will be used to compare the safety and
effectiveness of the LAL.
Inclusion Criteria:
- Must sign a written Informed Consent form and be willing to undergo cataract surgery
for the bilateral implantation of an intraocular lens (IOL).
- Between the ages of 40 and 80 inclusive on the day the cataract surgery is performed.
- History of Laser-Assisted In Situ Keratomileusis (LASIK), Photorefractive Keratectomy
(PRK), Laser-Assisted Subepithelial Keratomileusis (LASEK), Epi-LASIK, or Epi-LASEK
more than 1 year prior in both eyes.
- Cataract causing reduction in best corrected distance visual acuity (BCDVA) to a level
of 20/40 or worse with or without a glare source in both eyes.
- Willing and able to comply with the requirements for study specific procedures and
visits.
- Able to complete a written questionnaire in English.
Exclusion Criteria:
- Prior history of Intacs, RK, CK, AK, Phakic IOL (ICL), Refractive Lens Exchange (RLE),
or Corneal Inlay in either eye.
- Pre-existing macular disease in either eye.
- Patients with sufficiently dense cataracts that preclude examination of the macula in
either eye.
- History of uveitis in either eye.
- Evidence of ectasia in either eye.
- Previous intraocular surgery in either eye. Eyes with previous pterygium excision are
permitted as long as the pterygium did not extend more than 2mm onto the cornea from
the limbus.
- Subjects taking systemic medication that may increase sensitivity to UV light such as
tetracycline, doxycycline, psoralens, amiodarone, phenothiazines, chloroquine,
hydrochlorothiazide, hypericin, ketoprofen, piroxicam, lomefloxacin, and methoxsalen.
LDD treatment in patients taking such medications may lead to irreversible phototoxic
damage to the eye. This is only a partial list of photosensitizing medications. Please
evaluate all medications that the patient is taking for this effect prior to
consideration for implantation.
- Subjects taking a systemic medication that is considered toxic to the retina such as
tamoxifen.
- History of ocular herpes simplex virus in either eye.
We found this trial at
    6
    sites
	
									3900 Essex Lane
Houston, Texas 77027
	
			
					Houston, Texas 77027
Principal Investigator: Steven Slade, MD, FACS
			
						
										Phone: 713-626-5544
					Click here to add this to my saved trials
	 
  
								Brecksville, Ohio 44141			
	
			
					Principal Investigator: William F Wiley, MD
			
						
										Phone: 216-503-6535
					Click here to add this to my saved trials
	 
  
								Leawood, Kansas 66211			
	
			
					Principal Investigator: John F Doane, MD
			
						
										Phone: 816-350-6903
					Click here to add this to my saved trials
	 
  
								Salt Lake City, Utah 84107			
	
			
					Principal Investigator: Robert J Cionni, MD
			
						
										Phone: 801-266-2283
					Click here to add this to my saved trials
	 
  
								San Antonio, Texas 78229			
	
			
					Principal Investigator: James D Lehmann, MD
			
						
										Phone: 210-614-3600
					Click here to add this to my saved trials
	 
  
								Sioux Falls, South Dakota 57108			
	
			
					Principal Investigator: Vance Thompson, MD, FACS
			
						
										Phone: 605-361-3937
					Click here to add this to my saved trials
	